New antibody drug targets Hard-to-Treat cancers

NCT ID NCT06178614

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new drug called JNJ-87890387 in people with advanced solid tumors that have spread or cannot be removed. The drug is designed to help the immune system attack cancer cells. The main goals are to find a safe dose and to check for side effects. About 200 adults with certain types of kidney, ovarian, uterine, colorectal, or lung cancer may join.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

childhood kidney cell carcinoma colorectal adenocarcinoma endometrial endometrioid adenocarcinoma lung adenocarcinoma neoplasm ovarian endometrioid adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Centre Leon Berard

    RECRUITING

    Lyon, 69008, France

  • Hosp Univ Vall D Hebron

    RECRUITING

    Barcelona, 08035, Spain

  • Hosp. Univ. 12 de Octubre

    RECRUITING

    Madrid, 28041, Spain

  • Institut Gustave Roussy

    RECRUITING

    Villejuif, 94805, France

  • Sarah Cannon Research Institute

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Start Midwest

    RECRUITING

    Grand Rapids, Michigan, 49546, United States